DLA Piper acted as US counsel to Zealand Pharma, a Danish biotechnology company focused on the discovery and development of peptide-based medicines, in its upsized equity offering of 8.35 million new ordinary shares, which raised gross proceeds of US$1 billion and priced on June 25, 2024. The new shares are expected to be admitted to trading and official listing on Nasdaq Copenhagen on July 1, 2024.

“Leading growth companies around the globe look to DLA Piper for our cross-border capabilities, capital markets prowess and deep biopharma industry experience. We are pleased to have advised Zealand Pharma in its significant capital raise,” said Josh Kaufman, co-chair of DLA’s Capital Markets and Public Companies Advisory Practice, who led the deal team with partner Steve Alicanti out of New York.

The DLA Piper team also included partner Frank Mugabi and associate Andrew Wolfe (New York) and associate John Wei (Boston).

DLA Piper advises on all aspects of financing, across borders, sectors and financial products. The firm’s lawyers advise issuers, underwriters, selling shareholders, sponsors, arrangers, lead managers, originators, dealers, trustees and depositaries on a broad range of capital markets offerings, including equity, equity-linked and debt securities, structured and project financings and securitizations.